STRATA Skin Sciences to Participate in the Benchmark Company 13th Annual Discovery Investor Conference

SSKN 12.05.2024

Full Press ReleaseSEC FilingsOur SSKN Tweets

About Gravity Analytica

Recent News

  • 12.05.2024 - STRATA Skin Sciences to Participate in the Benchmark Company 13th Annual Discovery Investor Conference
  • 11.13.2024 - STRATA Skin Sciences - Third Quarter 2024 Earnings Conference Call
  • 11.13.2024 - STRATA Skin Sciences Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Recent Filings

  • 12.18.2024 - EFFECT Notice of Effectiveness
  • 12.16.2024 - CORRESP Correspondence
  • 12.11.2024 - EX-99.1 EX-99.1

HORSHAM, Pa.,Dec. 05, 2024(GLOBE NEWSWIRE) --STRATA Skin Sciences, Inc.(“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that President and Chief Executive Officer Dr.Dolev Rafaeliwill participate in theBenchmark Company13th AnnualDiscovery Investor Conferencethat is being held onWednesday, December 11, 2024, at theNew York Athletic ClubinNew York City.

Dr. Rafaeliwill host one-on-one meetings with analysts and investors throughout the day. To schedule a one-on-one meeting withDr. Rafaeli, attendees should contact theirBenchmark Companyrepresentative. Investors can attend the conference by registeringhere.

AboutSTRATA Skin Sciences

STRATA Skin Sciencesis a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC®excimer laser, VTRAC®lamp systems, and the TheraClear®X Acne Therapy System.

STRATA is proud to offer these exciting technologies in theU.S.through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure (versus an equipment purchase), installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’sSECreports on Forms 10-Q and 10-K. Givensuch uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review itsSECdisclosures available atwww.sec.govandwww.strataskinsciences.com.

Investor Contact:CORE IR516-222-2560IR@strataskin.com

Primary Logo

Source: STRATA Skin Sciences, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com